2,3,5-三苄氧基-D-核糖 | 54623-25-5

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3,5-三苄氧基-D-核糖
• 中文别名: 2,3,5-三-O-苄基-D-呋喃核糖
• 英文名称: 2,3,5-tri-O-benzyl-D-ribose
• 英文别名: (2R,3R,4R)-4-hydroxy-2,3,5-tris(phenylmethoxy)pentanal
• CAS: 54623-25-5
• 化学式: C₂₆H₂₈O₅
• 分子量: 420.505
• InChiKey: XUCNSIRQCBFBHF-UODIDJSMSA-N

物化性质

• 沸点：
  591.5±50.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  31
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2912499000
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2,3,5-三苄氧基-D-核糖 在 一水合肼 作用下， 以 甲醇 为溶剂， 生成 2,3,5-Tri-O-benzyl-D-ribosehydrazon
  参考文献：
  名称：

  糖基肼，2。

  摘要：

  达斯ringoffene d-Ribosehydrazon 5，DAS MIT巢穴ringgeschlossenen Ribosylhydrazinen 3，4，7 UND 8 IM Gleichgewicht steht，bildet MITβ-Dicarbonylverbindungen keine Pyrazolnucleoside。我们的合成方法是由Herstellung von Nucleosiden Gelingt的Jedoch dann和Freien合成的。Die dazu hergestellten D-Ribosehydrazon-derivate 13a-f stehen mit den entsprechenden Ribofuranosylhydrazinen 12和14 im Gleichgewicht。Sie liefern mitβ-Dimethoxyverbindungenje

  DOI：

  10.1002/cber.19771100704
• 作为产物：
  描述：

  甲基 2,3,5-三-O-苄基-D-呋喃核糖苷 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 2,3,5-三苄氧基-D-核糖
  参考文献：
  名称：

  糖基肼，2。

  摘要：

  达斯ringoffene d-Ribosehydrazon 5，DAS MIT巢穴ringgeschlossenen Ribosylhydrazinen 3，4，7 UND 8 IM Gleichgewicht steht，bildet MITβ-Dicarbonylverbindungen keine Pyrazolnucleoside。我们的合成方法是由Herstellung von Nucleosiden Gelingt的Jedoch dann和Freien合成的。Die dazu hergestellten D-Ribosehydrazon-derivate 13a-f stehen mit den entsprechenden Ribofuranosylhydrazinen 12和14 im Gleichgewicht。Sie liefern mitβ-Dimethoxyverbindungenje

  DOI：

  10.1002/cber.19771100704

文献信息

• Derivatives of hydrazino-monosaccharides and aldohexoses which are
  申请人：Byk Gulden Lomberg Chemische Fabrik GmbH

  公开号：US04021542A1

  公开（公告）日：1977-05-03

  Substituted hydrazino- and pyrazolo-aldopentoses and aldohexoses, which are useful as intermediates for preparing compounds, as compounds which lower the uric acid level in the blood, and as bactericides, are provided. The substituted hydrazino compounds also enter into chemical reactions which are not possible with their unsubstituted counterparts.

  提供了替代的肼基和吡唑基醛基五糖和六糖，它们可作为制备化合物的中间体，降低血液中尿酸水平的化合物，以及杀菌剂。这些替代的肼基化合物还参与了无法与其未取代的对应物发生的化学反应。
• GLYCOSYLATED CHLORAMBUCIL ANALOGS AND USES THEREOF
  申请人：Thorson Jon S.

  公开号：US20120094946A1

  公开（公告）日：2012-04-19

  A library of glycosylated chlorambucil analogs which are useful as anti-tumor and/or anti-metastatic agents is disclosed. The glycosylated chlorambucil analogs have the general formula wherein represents a reducing sugar moiety.

  揭示了一种作为抗肿瘤和/或抗转移药物有用的葡萄糖基氯氨丁醇类似物的图书馆。这些葡萄糖基氯氨丁醇类似物具有一般公式，其中表示还原糖基团。
• Oligonucleotides comprising a modified or non-natural nucleobase
  申请人：Manoharan Muthiah

  公开号：US20060035254A1

  公开（公告）日：2006-02-16

  One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-natural nucleobase. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.

  本发明的一个方面涉及含有至少一个非自然碱基的双链寡核苷酸。在某些实施例中，非自然碱基可以是二氟基甲苯基、硝基吲哚基、硝基吡咯基或硝基咪唑基。在一个首选实施例中，非自然碱基是二氟基甲苯基。在某些实施例中，双链寡核苷酸中的两个寡核苷酸链中只有一个含有非自然碱基。在某些实施例中，双链寡核苷酸中的两个寡核苷酸链都独立地含有非自然碱基。在某些实施例中，寡核苷酸链包含至少一个修饰的糖基。本发明的另一个方面涉及含有至少一个非自然碱基的单链寡核苷酸。在一个首选实施例中，非自然碱基是二氟基甲苯基。在某些实施例中，取代了核苷中天然存在的核糖糖基的是己糖糖基、多环杂烷基环或环己烯基团。在某些实施例中，寡核苷酸中的至少一个磷酸酯键被磷酸硫酯键取代。
• OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE
  申请人：MANOHARAN Muthiah

  公开号：US20090281298A1

  公开（公告）日：2009-11-12

  One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-natural nucleobase. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.

  本发明的一个方面涉及至少包含一种非天然核碱基的双链寡核苷酸。在某些实施例中，非天然核碱基是二氟基甲苯基、硝基吲哚基、硝基吡咯基或硝基咪唑基。在一个首选实施例中，非天然核碱基是二氟基甲苯基。在某些实施例中，仅有双链寡核苷酸中的两个寡核苷酸链中的一个包含非天然核碱基。在某些实施例中，包含双链寡核苷酸的两个寡核苷酸链独立地包含非天然核碱基。在某些实施例中，寡核苷酸链包括至少一个修饰的糖基团。本发明的另一个方面涉及至少包含一种非天然核碱基的单链寡核苷酸。在一个首选实施例中，非天然核碱基是二氟基甲苯基。在某些实施例中，核苷中天然存在的核苷糖被替换为六碳糖、多环杂基烷基环或环己烯基团。在某些实施例中，寡核苷酸中的至少一个磷酸酯连接被替换为磷酸硫酯连接。
• Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
  申请人：Manoharan Muthiah

  公开号：US20070054279A1

  公开（公告）日：2007-03-08

  One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.

  本发明的一个方面涉及一种双链寡核苷酸，其中至少一个配体被系在改变或非天然核碱基上。在某些实施例中，非天然核碱基是二氟基甲苯基、硝基吡咯基或硝基咪唑基。在某些实施例中，配体是类固醇或芳香化合物。在某些实施例中，只有双链寡核苷酸中的两个寡核苷酸链之一包含系在改变或非天然核碱基上的配体。在某些实施例中，双链寡核苷酸中的两个寡核苷酸链都独立地包含系在改变或非天然核碱基上的配体。在某些实施例中，寡核苷酸链包括至少一个修饰糖基。本发明的另一个方面涉及一种单链寡核苷酸，其中至少一个配体被系在改变或非天然核碱基上。在某些实施例中，非天然核碱基是二氟基甲苯基、硝基吡咯基或硝基咪唑基。在某些实施例中，配体是类固醇或芳香化合物。在某些实施例中，核苷酸中自然存在的核苷糖被替换为六糖、多环杂基烷基环或环己烯基团。在某些实施例中，寡核苷酸中至少一个磷酸酯键被磷酸硫酯键所替代。